株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

受容体型チロシンキナーゼERBB4:パイプライン製品の分析

Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 363580
出版日 ページ情報 英文 151 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.10円で換算しております。
受容体型チロシンキナーゼERBB4:パイプライン製品の分析 Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 151 Pages
概要

当レポートでは、受容体型チロシンキナーゼERBB4を標的とした治療薬の開発に関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

受容体型チロシンキナーゼERBB4の概要

治療薬の開発

受容体型チロシンキナーゼERBB4:開発中の製品 - 開発段階別

受容体型チロシンキナーゼERBB4:開発中の製品 - 治療範囲別

受容体型チロシンキナーゼERBB4:開発中の製品 - 適応症別

受容体型チロシンキナーゼERBB4:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

受容体型チロシンキナーゼERBB4:企業で開発中の製品

受容体型チロシンキナーゼERBB4:大学/機関で開発中の製品

受容体型チロシンキナーゼERBB4:治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

受容体型チロシンキナーゼERBB4の治療薬開発に従事している企業

  • Aslan Pharmaceuticals Pte. Ltd.
  • Boehringer Ingelheim GmbH
  • GamaMabs Pharma S.A.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • HEC Pharm Co., Ltd.
  • Jiangsu Kanion Pharmaceutical Co., Ltd.
  • Minerva Neurosciences, Inc.
  • Pfizer Inc.
  • Puma Biotechnology, Inc.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Zensun (Shanghai) Sci & Tech Co., Ltd.

薬剤プロファイル

受容体型チロシンキナーゼERBB4:休止中のプロジェクト

受容体型チロシンキナーゼERBB4:開発が中止された製品

受容体型チロシンキナーゼERBB4:主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
  • Pipeline by Avexegen Therapeutics Inc, H2 2019
  • Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019
  • Pipeline by HEC Pharm Co Ltd, H2 2019
  • Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Minerva Neurosciences Inc, H2 2019
  • Pipeline by Pfizer Inc, H2 2019
  • Pipeline by Puma Biotechnology Inc, H2 2019
  • Pipeline by XuanZhu Pharma Co Ltd, H2 2019
  • Pipeline by Yumab GmbH, H2 2019
  • Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC2001TDB

Summary

According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2019'; Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-4 is an enzyme that in humans is encoded by the ERBB4 gene. Receptor tyrosine-protein kinase erbB-4 is a receptor tyrosine kinase that is a member of the epidermal growth factor receptor subfamily. it plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. It is required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation, normal development of the embryonic central nervous system, especially for normal neural crest cell migration, normal axon guidance, mammary gland differentiation, induction of milk proteins and lactation. It acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors.

The report 'Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2019' outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 4, 4, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal and Hematological Disorders which include indications Breast Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Colorectal Cancer, Esophageal Cancer, Ovarian Cancer, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Esophageal Squamous Cell Carcinoma (ESCC), Gallbladder Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, High-Grade Glioma, Pancreatic Cancer, Adenocarcinoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Bladder Cancer, Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary), Cervical Cancer, Chordoma, Chronic Heart Failure, Crohn's Disease (Regional Enteritis), Diastolic Heart Failure, Endometrial Cancer, Ependymoma, Fanconi Anemia, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hypopharyngeal Cancer, Laryngeal Cancer, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Low-Grade Astrocytoma, Lung Adenocarcinoma, Lung Cancer, Medulloblastoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Necrotizing Enterocolitis, Neuroblastoma, Non-Small Cell Lung Carcinoma, Oligodendroglioma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Papillary Thyroid Cancer, Paranasal Sinus And Nasal Cavity Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Pituitary Tumor, Primitive Neuroectodermal Tumor (PNET), Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rhabdomyosarcoma, Sarcomas, Stroke, Systolic Heart Failure, Ulcerative Colitis, Urinary Tract Cancer and Uterine Cancer.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
  • The report reviews Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Overview
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
  • Aslan Pharmaceuticals Ltd
  • Avexegen Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Hanmi Pharmaceuticals Co Ltd
  • HEC Pharm Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Minerva Neurosciences Inc
  • Pfizer Inc
  • Puma Biotechnology Inc
  • XuanZhu Pharma Co Ltd
  • Yumab GmbH
  • Zensun (Shanghai) Sci & Tech Co Ltd
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Drug Profiles
  • afatinib dimaleate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dacomitinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FCN-411 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KBP-5209 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MIN-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Target ErbB4 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • neratinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neucardin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NRG-4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NT-113 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PB-357 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • poziotinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SKLB-1206 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • varlitinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XZP-5491 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • yinlitinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Z-650 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Dormant Products
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Discontinued Products
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer